Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Bioventus (BVS) Long-Term Debt Issuances (2020 - 2025)

Bioventus filings provide 5 years of Long-Term Debt Issuances readings, the most recent being $15.0 million for Q3 2025.

  • On a quarterly basis, Long-Term Debt Issuances changed N/A to $15.0 million in Q3 2025 year-over-year; TTM through Dec 2025 was $45.0 million, a N/A change, with the full-year FY2025 number at $31.9 million, changed N/A from a year prior.
  • Long-Term Debt Issuances hit $15.0 million in Q3 2025 for Bioventus, roughly flat from $15.0 million in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $257.5 million in Q4 2021 to a low of -$64.0 million in Q4 2023.
  • Median Long-Term Debt Issuances over the past 4 years was $15.0 million (2022), compared with a mean of $38.2 million.
  • The widest YoY moves for Long-Term Debt Issuances: up 226.67% in 2023, down 72.56% in 2023.
  • Bioventus' Long-Term Debt Issuances stood at $257.5 million in 2021, then crashed by 78.77% to $54.7 million in 2022, then tumbled by 217.09% to -$64.0 million in 2023, then surged by 123.44% to $15.0 million in 2025.
  • The last three reported values for Long-Term Debt Issuances were $15.0 million (Q3 2025), $15.0 million (Q2 2025), and $15.0 million (Q1 2025) per Business Quant data.